Anna Katharina Frank

Anna Katharina Frank

Auto-generated profile, based on publicly available information

Anna Katharina Frank

Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery and Specialized Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2019 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
OTOlivia C. Tysoe
Olivia C. Tysoe
AJAlexander W. Justin
Alexander W. Justin
TBTeresa Brevini
Teresa Brevini
SCSi Emma Chen
Si Emma Chen
KMKrishnaa T. Mahbubani
Krishnaa T. Mahbubani
FSFotios Sampaziotis
Fotios Sampaziotis

6 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
Mathias BusekMathias Busek
Mathias Busek
AAAleksandra Aizenshtadt
Aleksandra Aizenshtadt
TKT. Koch
T. Koch
AFA. Frank
A. Frank
LDL. Delon
L. Delon
SKStefan Johannes Karl Krauss
Stefan Johannes Karl Krauss
Current organ-on-a-chip (OoC) systems mimic important aspects of specific organ and tissue functions, however, many commercial and academic devices are either too simple for advanced assays or require a complicated support set-up including external driving systems such as pumps and tubing that hamper scalability and robustness. We have developed a novel, pump-less directional flow recirculating organ-on-a-chip (rOoC) platform that creates continuous or pulsed directional gravity-driven flow by a combination of a 3D-tilting system and an optimized microfluidic layout. The rOoC platform allows growing and connecting tissue or organ representations on-chip with the possibility of incorporating barrier functions, gradients, and circulating cells. Using the rOoC platform we demonstrate simple and reproducible endothelialisation, hepatic organoid integration, and the first steps of vascularization of 3D organ representations on-chip.

20 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
HHHenry William Hoyle
Henry William Hoyle
AFAnna Katharina Frank
Anna Katharina Frank
EAEnya Amundsen-Isaksen
Enya Amundsen-Isaksen
SPSarah Peisl
Sarah Peisl
OHOline Øie Hovland
Oline Øie Hovland
EMEspen Melum
Espen Melum
Background and aims: Model systems for bile duct disorders are needed for testing therapeutic interventions. Current models have poor human relevance or limited potential for recreating the complex bile duct microenvironment at scale. We aimed to generate a humanized microphysiological system to model and treat cholangiopathies. Methods: An in vitro bile duct was created using 3D printed microfluidic chips containing a collagen-embedded canal seeded with patient-derived primary human cholangiocytes. Barrier permeability and compound transport across the epithelium was measured, and disruption of the barrier was performed with lipopolysaccharide treatment. The duct was challenged with the known hepatotoxicant Chlorpromazine. Biliatresone was used to model biliary-atresia and treated using N-acetyl-L-cysteine. Results: Cholangiocytes in the bile duct chip established a tight, polarized epithelial barrier. Verapamil and Linerixibat inhibited transport of rhodamine 123 and cholyl-lys-fluorescein respectively with 66 % (p = 0.0004) and 57 % (p = 0.03) reduction. 10 µg/mL lipopolysaccharide led to a loss of epithelial barrier integrity, measured by an increase of over 1000 % in leakage of both 3 kDa (p = 0.0002) and 10 kDa dextran (p = 0.0001) along with upregulation of cytokines. Chlorpromazine displayed dose-dependent toxicity with EC50 values of 84, 140 and 96 µM for three patient lines. Biliatresone induced a dose-dependent abnormal phenotype with loss of viability. The induced phenotype could be treated with N-acetyl-L-cysteine, improving viability from 23 % to 59 % (p < 0.0001) with treatment of 2 µg/mL Biliatresone. Conclusions: Our novel platform allows complex studies of bile duct biology, testing of off-target effects from drugs and treatment of a disease phenotype.